Profile data is unavailable for this security.
About the company
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
- Revenue in USD (TTM)4.60m
- Net income in USD-7.68m
- Incorporated1981
- Employees13.00
- LocationInMed Pharmaceuticals IncSUITE 310, 815 W. HASTINGS STREETVANCOUVER V6C 1B4CanadaCAN
- Phone+1 (604) 669-7207
- Fax+1 (778) 945-6800
- Websitehttps://www.inmedpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phio Pharmaceuticals Corp | 0.00 | -8.68m | 2.42m | 8.00 | -- | 0.38 | -- | -- | -23.77 | -23.77 | 0.00 | 7.40 | 0.00 | -- | -- | 0.00 | -98.62 | -71.92 | -126.86 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Peak Bio Inc | 354.02k | -4.63m | 2.54m | -- | -- | -- | -- | 7.19 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Emmaus Life Sciences Inc | 19.97m | -5.26m | 2.55m | 51.00 | -- | -- | -- | 0.1276 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.40m | 2.57m | 1.00 | -- | 3.24 | -- | -- | -1.45 | -1.45 | 0.00 | 0.1774 | 0.00 | -- | -- | 0.00 | -152.72 | -74.49 | -206.36 | -92.56 | -- | -- | -- | -- | -- | -17.09 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Qrons Inc | 0.00 | -860.04k | 2.59m | 2.00 | -- | -- | -- | -- | -0.0632 | -0.0632 | 0.00 | -0.088 | 0.00 | -- | -- | 0.00 | -9,368.63 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -9.21 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
| Pharmagreen Biotech Inc | 4.36k | -403.84k | 2.65m | 0.00 | -- | -- | -- | 608.85 | -0.0007 | -0.0007 | 0.00001 | -0.0034 | 0.0366 | 0.2274 | 7.33 | -- | -339.07 | -523.11 | -- | -- | 54.36 | -- | -9,263.30 | -307,598.30 | 0.0004 | -2.15 | -- | -- | -- | -- | 35.03 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 4.60m | -7.68m | 2.78m | 13.00 | -- | 0.202 | -- | 0.605 | -1.33 | -1.33 | 0.6027 | 1.03 | 0.3546 | 2.44 | 14.99 | -- | -59.20 | -92.09 | -69.92 | -113.17 | 23.94 | -- | -166.94 | -543.29 | 3.78 | -- | 0.00 | -- | 11.18 | -- | 3.42 | -- | -19.10 | -- |
| Halberd Corp | 281.24k | 25.34k | 2.80m | 3.00 | 1.90 | -- | 110.28 | 9.95 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Avenue Therapeutics Inc | 0.00 | -5.87m | 2.82m | 3.00 | -- | 0.492 | -- | -- | -3.02 | -3.02 | 0.00 | 4.00 | 0.00 | -- | -- | 0.00 | -177.94 | -186.91 | -- | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -11.60m | 3.04m | 10.00 | -- | 2.10 | -- | -- | -17.91 | -17.91 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -199.23 | -70.80 | -321.87 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -15.90m | 3.04m | 9.00 | -- | 1.17 | -- | -- | -29.75 | -29.75 | 0.00 | 0.6939 | 0.00 | -- | -- | 0.00 | -112.35 | -- | -253.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 98.89 | -- | -- | -- |
| Oragenics Inc | 7.47k | -19.52m | 3.12m | 5.00 | -- | -- | -- | 417.30 | -6.99 | -6.99 | 0.0023 | 0.2377 | 0.0013 | -- | -- | 1,494.00 | -349.31 | -97.60 | -451.26 | -106.24 | -- | -- | -261,261.60 | -36,169.75 | -- | -- | 0.00 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Talis Biomedical Corp | 408.00k | -51.03m | 3.13m | 99.00 | -- | 0.0645 | -- | 7.68 | -28.02 | -28.02 | 0.224 | 26.69 | 0.0042 | -- | 1.53 | 4,121.21 | -52.13 | -68.18 | -57.23 | -74.22 | 95.10 | -- | -12,506.37 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Mar 2024 | 361.73k | 4.33% |
| Armistice Capital LLCas of 31 Mar 2024 | 266.97k | 3.19% |
| Virtu Americas LLCas of 30 Jun 2024 | 86.68k | 1.04% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 15.42k | 0.19% |
| Citadel Securities LLCas of 31 Mar 2024 | 12.73k | 0.15% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 200.00 | 0.00% |
| BofA Securities, Inc.as of 31 Mar 2024 | 100.00 | 0.00% |
| TD Waterhouse Canada, Inc.as of 30 Jun 2024 | 85.00 | 0.00% |
| UBS Securities LLCas of 31 Mar 2024 | 41.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 27.00 | 0.00% |
